Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca UK Ltd.

Division of AstraZeneca PLC

Latest From AstraZeneca UK Ltd.

Speedy EU Assessment On Cards For AZ’s Durvalumab

AstraZeneca is hoping that when it files for approval in the EU of its PD-L1 blocker, Imfinzi (durvalumab), for Stage III lung cancer, it will be given accelerated assessment on the back of the PACIFIC data.

ImmunoOncology Regulation

WuXi Biologics Readies For Hong Kong IPO

As predicted by Scrip last July, WuXi AppTec has moved one step closer to spinning out its biologics unit through an IPO on the Hong Kong equity market, while its main business unit is also proceeding with plans for a China domestic relisting.

China Companies

Latest Entrant To UK Early Access Scheme Is AstraZeneca's Osimertinib

Lung cancer drug, recently approved in the US as Tagrisso, is fourth product made available early to UK patients as it awaits EU marketing approval.

BioPharmaceutical United Kingdom

International Group Finds Harmony In Benefit-Risk Assessment Framework

Sponsors and regulators continue to develop methodologies with a range of complexity for presenting, communicating and discussing a drug’s risks and benefits.

BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Contact Info
  • AstraZeneca UK Ltd.
    Phone: (44) 1582 837 837
    Horizon Pl.
    Luton, LU1 3LU